NSE ZYDUSLIFE · BSE 532321 · Biotechnology & Drugs · NIFTY 500

Zydus Lifesciences Share Price

Market closed · NSE price as of Thu 24 Sep, 10:29 AM IST
₹1,180.30 ▲ +₹10.53 · 0.90%
Day range · 24 Sep
₹1,162.65Low₹1,191.00High
52-week range
₹835.85Low · 2 Apr 2026₹1,205.65High · 12 Aug 2026

Zydus Lifesciences Overview

Where the price stands, how it has moved and how it sits against its averages.

Zydus Lifesciences shares last traded at ₹1,180.30 on the NSE, up 0.90% on the day. That is 2.1% below the 52-week high of ₹1,205.65 and 41.2% above the 52-week low of ₹835.85. The stock trades at 26.08× earnings, below the sector average of 36.50. Its market value is ₹1,17,705 Cr.

Price returns

1 Day▲ +0.90%
1 Week0.00%
This month▲ +0.76%
3 Months▲ +6.44%
6 Months▲ +29.48%
This year▲ +27.97%
1 Year▲ +11.99%

Against the market: 1 Month ▲ +5.34% · 3 Months ▲ +9.52% · 6 Months ▲ +30.25% · This year ▲ +45.74% · 1 Year ▲ +22.87%

Shading grows with the size of the move. We ask our data provider for a newer price every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next check from Fri 16 Oct, 9:15 AM. Its quotes are not real-time — the time at the top shows how current the price is.

Moving averages — price is above 6 of 6

  1. Today's price₹1,180.30
  2. 5-day average₹1,145.18 ▲ price 3.1% above
  3. 20-day average₹1,141.98 ▲ price 3.4% above
  4. 50-day average₹1,135.26 ▲ price 4.0% above
  5. 10-day average₹1,133.47 ▲ price 4.1% above
  6. 100-day average₹1,095.07 ▲ price 7.8% above
  7. 300-day average₹1,000.60 ▲ price 18.0% above

Each average is the mean closing price over that many trading days; averages above the current price sit higher on the ladder.

Zydus Lifesciences Financial Results

Revenue and net profit in ₹ crore, with the full statements underneath.

Revenue₹ crore
27,148
Net profit₹ crore · losses below zero
5,040

Year by year

Fiscal yearRevenueGrowthNet profitNet marginEPSDividend
FY 2026 ₹27,148 Cr ▲ +16.8% ₹5,040 Cr 18.6% ₹50.09 ₹1.00
FY 2025 ₹23,242 Cr ▲ +18.9% ₹4,526 Cr 19.5% ₹44.97 ₹11.00
FY 2024 ₹19,547 Cr ▲ +13.4% ₹3,860 Cr 19.7% ₹37.91 ₹3.00
FY 2023 ₹17,237 Cr ▲ +14.1% ₹1,960 Cr 11.4% ₹19.35 ₹6.00
FY 2022 ₹15,110 Cr ▲ +4.9% ₹4,487 Cr 29.7% ₹21.90 ₹2.50
FY 2021 ₹14,404 Cr ▲ +1.1% ₹2,134 Cr 14.8% ₹21.51 ₹3.50
FY 2020 ₹14,253 Cr — ₹1,177 Cr 8.3% ₹11.49 ₹3.50

Balance sheet — FY26

Owes (liabilities)Shareholders' equity
48%
52%
  • Total assets₹52,407 Cr
  • Total liabilities₹25,295 Cr
  • Shareholders' equity₹27,111 Cr
  • Total debt₹12,496 Cr
  • Cash & investments₹7,188 Cr
  • Current ratio1.27×
  • Revenue growth, 5 yr13.52% a year
  • EPS growth, 5 yr18.42% a year
  • Operating margin (TTM)16.71%
  • Net margin (TTM)15.71%

Cash flow — FY26

Operating activities
▲ ₹2,307 Cr
Investing activities
▼ −₹8,296 Cr
Financing activities
▲ ₹5,807 Cr
Free cash flow
▼ −₹1,087 Cr
Net change in cash
▲ ₹28 Cr

Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.

Full financial statements, FY20–FY26
₹ croreFY20FY21FY22FY23FY24FY25FY26
Total revenue14,253.1014,403.5015,109.9017,237.4019,547.4023,241.5027,148.40
Cost of revenue5,507.905,442.706,248.507,056.307,041.007,231.208,390.90
Gross profit8,745.208,960.808,861.4010,181.1012,506.4016,010.3018,757.50
Operating expenses12,515.1011,873.0012,523.1014,988.8015,025.9017,481.8021,878.40
Operating income1,738.002,530.502,586.802,248.604,521.505,759.705,270.00
Depreciation696.50669.60713.00722.70764.10915.801,408.00
Profit before tax1,495.402,399.202,838.102,589.704,808.906,026.706,621.10
Tax319.80193.60511.70587.80977.501,411.901,594.70
Net profit1,176.602,133.604,487.301,960.303,859.504,525.505,040.00
EPS (₹)11.4921.5121.9019.3537.9144.9750.09
Dividend per share (₹)3.503.502.506.003.0011.001.00

Zydus Lifesciences vs Peers

Side by side with other biotechnology & drugs companies. The small bars compare each column.

CompanyPriceChangeMarket capP/EP/BROE (5 yr)Net marginDiv. yield
Zydus Lifesciences This stock ₹1,180.30 ▲ +0.90% ₹1,17,705 Cr 26.08 4.38 17.90% 15.71% 0.08%
Sun Pharmaceutical Industries ₹1,853.00 ▼ −0.64% ₹4,44,586 Cr 38.40 5.55 14.22% 19.12% 0.83%
Divi's Laboratories ₹9,613.00 ▲ +0.17% ₹2,55,195 Cr 73.32 11.48 16.87% 24.32% 0.41%
Torrent Pharmaceuticals ₹4,935.00 ▼ −0.90% ₹1,87,705 Cr 72.73 19.22 23.00% 15.29% 0.80%
Cipla ₹1,404.00 ▲ +1.74% ₹1,13,423 Cr 27.57 3.33 14.47% 13.74% 0.92%
Lupin ₹2,098.00 ▼ −0.10% ₹95,934 Cr 19.12 4.98 12.70% 19.16% 0.74%

Peer prices and ratios as last reported by the data provider. Company names link to their own pages.

Shareholding Pattern

Who owns Zydus Lifesciences shares, quarter by quarter (latest on top).

PromoterFIIMFOther
Jun '26
75.0%
13.0%
Mar '26
Dec '25
HolderDec '25Mar '26Jun '26Change
Promoter75.00%75.00%75.01% ▲ +0.01 pts
FII7.06%6.95%6.89% ▼ −0.06 pts
MF4.71%4.88%5.12% ▲ +0.24 pts
Other13.23%13.17%12.98% ▼ −0.19 pts

Zydus Lifesciences Key Metrics

Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.

Zydus LifesciencesBenchmarkRule-of-thumb bands

Valuation The price against earnings, book value and sales

P/E (TTM)Price ÷ yearly earnings per share
26.08
▼ 29% below the sector average of 36.50
P/E, 12-month rangeLow 14.31 · high 26.57
96%
Today's P/E sits 96% of the way from its low to its high
P/BPrice ÷ book value per share
4.38
P/SMarket cap ÷ last 12 months' revenue
4.12
P/CFPrice ÷ cash flow per share
18.77
PEGP/E ÷ earnings growth rate
0.70

Profitability Of every ₹100 of sales, how much is kept?

Gross marginKept after the cost of goods
72.92%
▲ above its 5-yr average of 64.84%
Operating marginKept after running costs
16.71%
▼ below its 5-yr average of 19.93%
Pre-tax marginKept before tax
21.01%
▼ below its 5-yr average of 22.37%
Net marginKept as profit
15.71%
▼ below its 5-yr average of 17.40%

Returns & efficiency How well does it use its money?

Return on equityProfit on shareholders' money
19.74%
▲ above its 5-yr average of 17.90%
Return on assetsProfit on everything it owns
11.22%
▼ below its 5-yr average of 11.25%
Return on investmentProfit on long-term capital
16.76%
▲ above its 5-yr average of 16.55%
Return on capital employedProfit before interest and tax on equity + debt
19.83%

Growth Is the business getting bigger?

Revenue — last 12 months
+21.1%
▲ growing
Revenue — 3 yr, a year
+16.4%
▲ growing
Revenue — 5 yr, a year
+13.5%
▲ growing
Net profit — 3 yr, a year
+37.0%
▲ growing (off the scale)
Net profit — 5 yr, a year
+18.8%
▲ growing
EPS — last 12 months
−1.3%
▼ shrinking
EPS — 3 yr, a year
+37.3%
▲ growing (off the scale)
EPS — 5 yr, a year
+18.4%
▲ growing
Dividend — 3 yr, a year
−45.0%
▼ shrinking (off the scale)
Book value — 5 yr, a year
+16.3%
▲ growing

Financial strength Can it pay its bills and debts?

Debt to equityBorrowings for every ₹1 of shareholders' money
0.46×
✓ Low debt
Current ratioShort-term assets for every ₹1 due within a year
1.27×
• Adequate
Quick ratioLike the current ratio, without inventory
0.88×
• Adequate
Payout ratioShare of profit paid as dividend
2.00%
• Keeps most

Per share What each share stands for

EPS (TTM)
₹44.87
Book value
₹269.44
Cash flow
₹61.81
Dividend
₹1.00
Revenue
₹284.27

The share price is 4.38× the book value behind each share.

Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.

All 108 metrics from the data provider

Valuation

P/E excluding extraordinary items, most recent fiscal year23.36
Current Dividend Yield - Common Stock Primary Issue, LTM0.09
Price to Book - most recent fiscal year4.34
P/E Basic excluding extraordinary items - TTM24.80
P/E including extraordinary items - TTM26.08
P/E excluding extraordinary items low, trailing 12 months14.31
Price to Tangible Book - most fiscal year12.03
Dividend Yield - 5 Year Average0.65
Price to sales - most recent fiscal year4.30
Dividend Yield - indicated annual dividend divided by closing price0.09
Price to Cash Flow per share - trailing 12 month18.77
Peg Ratio0.70
P/E Normalized, most recent fiscal year21.68
P/E excluding extraordinary items high, trailing 12 months26.57
P/E excluding extraordinary items, most recent fiscal year quarter26.08
Price to sales - trailing 12 month4.08
Net Debt, LFY53,082.00

Per share

Dividend Per Share - 5 year average4.70
Cash Flow per share - trailing 12 month61.81
Cash Flow per share - most recent fiscal year63.95
EPS including extraordinary items - trailing 12 month44.87
EPS including extraordinary items - most recent fiscal year50.09
EBITD per share - trailing 12 month69.95
Revenue/share - trailing 12 month284.27
EPS excluding extraordinary items - trailing 12 month44.87
EPS Basic excluding extraordinary items - most recent fiscal year50.09
EPS Basic excluding extraordinary items - trailing 12 month44.87
Book value per share - most recent fiscal year269.43
Dividend per share - most recent fiscal year1.00
Revenue/share - most recent fiscal year269.80
EPS Normalized - most recent fiscal year53.97
Book value (tangible) per share - most recent fiscal year96.43
Dividends per share - trailing 12 month1.00
EPS excluding extraordinary items - most recent fiscal year50.09
Cash per share - most recent fiscal year71.43

Margins

Operating margin - trailing 12 month16.71
Gross Margin - 5 year average64.84
Operating margin - 1st historical fiscal year19.41
Operating Margin - 5 year average19.93
Net Profit Margin % - 1st historical fiscal year18.51
Gross Margin - 1st historical fiscal year69.09
Net Profit Margin % - trailing 12 month15.71
Net Profit Margin - 5 year average17.40
Pretax Margin - 5 year average22.37
Pretax margin - 1st historical fiscal year24.39
Pretax margin - trailing 12 month21.01
Free Operating Cash Flow/Revenue, 5 Year Average6.02
Gross Margin - trailing 12 month72.92

Growth

EPS Change %, TTM over TTM−1.27
Revenue growth rate, 5 year13.52
EPS growth rate, 5 year18.42
Revenue Change % - most recent quarter 1 year ago21.96
Growth rate% - dividend, 3 year−44.97
Growth rate% - EPS, 3 year37.31
Revenue/share (5 yr growth)13.91
Tangible Book Value, Total Equity, 5 Year CAGR8.65
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year Interim CAGR14.54
Capital Spending growth rate, 5 year31.78
Revenue Change %, TTM over TTM21.11
Growth rate% - Revenue, 3 year16.35
Book value per share growth rate, 5 year16.25
EPS Change % - most recent quarter 1 year ago−35.87
Net Profit Margin growth rate, 5 year3.87
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR16.14
Total Debt, 5 Year CAGR22.08

Financial strength

Free Cash Flow - most recent fiscal year−21,935.00
LT debt/equity - most recent fiscal year0.14
Quick ratio - most recent fiscal year0.88
Payout ratio - trailing 12 month2.23
Current ratio - most recent fiscal year1.27
Current EV/Free Cash Flow, LFY64.37
Total debt/total equity - most recent fiscal year0.46
Payout ratio - most recent fiscal year2.00

Returns & efficiency

Return on average equity - 5 year average17.90
Net Income/employee - trailing 12 month14,98,399.00
Revenue/employee - most recent fiscal year93,78,172.00
Return on investment - most recent fiscal year16.76
Return on average assets - most recent fiscal year11.22
Receivables turnover - most recent fiscal year5.74
Inventory turnover - most recent fiscal year1.66
Revenue/employee - trailing 12 month95,36,925.00
Return on average assets - 5 year average11.25
Net Income/employee - most recent fiscal year17,36,325.00
Asset turnover - most recent fiscal year0.61
Return on average equity - most recent fiscal year19.74
Return on investment - 5 year average16.55

Price & volume

Market Cap1,18,363.80
52 week Low Date2 Apr 2026
Price - 1 Day % Change0.67
Relative (S&P500) price percent change - 13 week9.52
Avg trading volume last 10 days1.14
Price - 13 week price percent change6.44
Price - 52 week price percent change11.99
Avg Trading Volume Last 3 months29.24
Price - 5 Day % Change5.65
Price % Change Month To Date0.76
Relative (S&P500) price percent change - 04 week5.34
52 week High Date12 Aug 2026
Price - 26 week price percent change29.48
PDATE23 Sep 2026
Price - YTD price percent change27.97
Relative (S&P500) price percent change - 52 week22.87
NPRICE1,170.10
Relative (S&P500) price percent change - 26 week30.25
52 week Low835.50
52 week High1,205.00
Beta0.63
Relative (S&P500) price percent change - Year to Date45.74

Dividends & Corporate Events

Payouts to shareholders, splits and bonus issues, and company meetings — newest first.

Dividend per share₹ per share, by fiscal year
₹11.00
₹1.00
  • Dividend yield0.08%
  • Payout ratio2.00%
  • 5-year average dividend₹4.70 a share
  • Latest dividend₹1.00 per share · 24 Jul 2026

Corporate calendar

  • MeetingAnnual General Meeting
  • BoardQuarterly Results
  • Dividend₹1.00 per share · 100% · Final dividend
  • BoardAudited Results, Dividend & Buy Back
  • BoardQuarterly Results
  • MeetingPostal Ballot
  • BoardQuarterly Results & Fund raising
  • MeetingAnnual General Meeting
Show 12 older events
  • BoardQuarterly Results
  • Dividend₹11.00 per share · 1,100% · Final dividend
  • BoardAudited Results & Final Dividend
  • BoardQuarterly Results
  • BoardQuarterly Results
  • MeetingAnnual General Meeting
  • Dividend₹3.00 per share · 300% · Final dividend
  • MeetingAnnual General Meeting
  • Dividend₹6.00 per share · 600% · Final dividend
  • MeetingAnnual General Meeting
  • Dividend₹2.50 per share · 250% · Final dividend
  • Dividend₹3.50 per share · 350% · Final dividend

About Zydus Lifesciences

Biotechnology & Drugs

Zydus Lifesciences Limited is an India-based life-sciences company with positions across pharmaceuticals and consumer wellness, supported by a MedTech franchise and a global footprint across United States, India and other international markets. Its pharmaceutical business includes integrated pharmaceutical operations with business encompassing the entire value chain in research, development, production, marketing and distribution of pharmaceutical products. Its product portfolio includes active pharmaceutical ingredients, human formulations, and animal health and veterinary. Its consumer products business includes development, production, marketing and distribution of differentiated health and wellness products. It provides biologicals manufacturing sites offering contract development and manufacturing organization services to biopharmaceutical companies globally. Its focused therapy areas include cardiology, anti-diabetes, super specialty areas of oncology and nephrology, and others.

Key people

  • Tushar ShroffChief Financial Officer
  • Dhaval Narendra SoniCompany Secretary, Compliance Officer
  • Sharvil Pankajbhai PatelManaging Director, Executive Director
  • Ganesh N. NayakExecutive Director

Company facts

  • NSE symbolZYDUSLIFE
  • BSE code532321
  • ISININE010B01027
  • IndustryBiotechnology & Drugs
  • IndexNIFTY 500
  • Market cap₹1,17,705 Cr
  • Revenue (FY26)₹27,148 Cr
  • Net profit (FY26)₹5,040 Cr

In the News

Recent headlines about Zydus Lifesciences — they open on Mint in a new tab.

Stock data comes from the exchange feed via our data provider. It is not real-time and can be delayed, so check the price with your broker before you trade. This page is for information and education only. It is not investment advice, research or a recommendation to buy, sell or hold any security. Investments in the securities market are subject to market risks; read all related documents carefully before investing. See all stocks →

Frequently Asked Questions

Zydus Lifesciences (NSE: ZYDUSLIFE) last traded at ₹1,180.30 on the NSE, up 0.90% (₹10.53) on the day, as of 24 Sep 2026, 10:29 AM IST. On the BSE it was ₹1,180.00. The day's range was ₹1,162.65 – ₹1,191.00.

Zydus Lifesciences's 52-week high is ₹1,205.65 (12 Aug 2026) and its 52-week low is ₹835.85 (2 Apr 2026). At ₹1,180.30 the share is 2.1% below its high and 41.2% above its low.

Zydus Lifesciences's market capitalisation is ₹1,17,705 Cr (₹1.18L Cr). It is part of the NIFTY 500 index.

Zydus Lifesciences's P/E ratio (trailing 12 months) is 26.08. The sector average is 36.50, so investors pay 29% less for each rupee of its earnings than for the average company in its sector. Its earnings per share (TTM) are ₹44.87.

Zydus Lifesciences shares are up 11.99% over the last year, up 27.97% so far this year, up 29.48% over 6 months, up 6.44% over 3 months. Over the last year the stock did 22.87% better than the market.

In FY26 (year to Mar 2026), Zydus Lifesciences reported revenue of ₹27,148 Cr (up 16.81% on the year before) and a net profit of ₹5,040 Cr. Earnings per share were ₹50.09.

Yes. Zydus Lifesciences's latest dividend is ₹1.00 per share (100%, final dividend), with an ex-date of 24 Jul 2026. The dividend yield is 0.08%. It has paid 6 dividends in the records shown on this page.

As of Jun 2026: Promoter 75.01%, FII 6.89%, MF 5.12%, Other 12.98%. Promoter holding rose by 0.01 percentage points from Mar 2026.

Zydus Lifesciences's listed peers in Biotechnology & Drugs include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Cipla, Lupin. By market capitalisation it ranks #4 of 6 in this group.

No. Zydus Lifesciences has debt — its debt-to-equity ratio is 0.46 and total debt was ₹12,496 Cr in FY26.